ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Preoperative serum LMTK3 as a novel biomarker in non-small cell lung cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 6 citations in OpenAlex.
- Article
- LMTK3 as a spatially regulated and stage-dependent biomarker in epithelial ovarian tumorigenesis.Molecular therapy. Oncology · 2026Article
- Evaluation of the Association between LMTK3 Gene Polymorphism and Breast Cancer Risk in the Indian Population.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- The Inhibitory Properties of a Novel, Selective LMTK3 Kinase Inhibitor.International journal of molecular sciences · 2023Article
- The multifaceted role of lemur tyrosine kinase 3 in health and disease.Open biology · 2021Review
- LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway.FEBS open bio · 2020Article
- LMTK3 confers chemo-resistance in breast cancer.Oncogene · 2018Article
- LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer.Molecular medicine reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lemur tyrosine kinase-3 (LMTK3) has been reported to be involved in tumor progression. The aim of this study was to determine the diagnostic and prognostic significances of preoperative serum LMTK3 in non-small cell lung cancer (NSCLC) patients. Sera were collected from 100 healthy volunteers (HV), 280 benign lung diseases (BLD) patients, and 524 NSCLC patients prior to operation. The serum LMTK3 level was detected by ELISA. We found that serum LMTK3 level was markedly elevated in NSCLC patients compared with controls. The receiver operating characteristic (ROC) curve suggests that serum LMTK3 is a good diagnostic and differential marker for discriminating NSCLC patients from BLD. NSCLC patients with LMTK3 level ≥6.85 ng/ml had significantly worse survival than patients with LMTK3 <6.85 ng/ml. In multivariate analysis, LMTK3 level ≥6.85 ng/ml was an independent factor of poor prognosis [hazard ratio (HR) = 2.95; p = 0.011] after adjusting for age, sex, smoking behavior, stage, and histology. The Kaplan-Meier survival curves showed the consistent trend. Preoperative serum LMTK3 is a novel diagnostic and independent prognostic biomarker in patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.